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19th CardioVascular Summit: TCTAP 2014often unavoidable. During this period, coronary collateral circulation be an important
alternative supply when the main blood vessels fail to provide adequate perfusion to
myocardial tissues due to occlusion. This study aims to determine the effect of
collateral circulation in MR Imaging-Veriﬁed Myocardial infarct size and myocardial
salvage index (MSI) in the acute phase of STEMI treated with PPCI.
Methods: Study was designed as cross-sectional study involving 33 STEMI patients
with symptoms < 12 hours who underwent successful PPCI. Samples were taken
consecutively from November 2012 to April at the National Cardiovascular Center
Harapan Kita Jakarta. Collateral ﬂow was gradded regarding to Rentrop classiﬁcation.
Patients were divided into 2 groups; Group A had absent or weak collateral ﬂow and
group B had signiﬁcant ﬂow. All patients underwent cardiac magnetic resonance
(CMR) to assess infarct size and MSI.
Results: In our study, 12out of 33 (36%) patients had signiﬁcant collateral circulation
(Rentrop grade2 or 3). Pre-infarction angina was a clinicalfactors associated with
recruitable collaterals(p<0,001). Infarct size expressed as percent LV mass (IS%LV)
was signiﬁcantly smaller in group B (14.2%vs. 23.3%; p ¼ 0.036). Extent of MSI was
signiﬁcantly higher in group B (0,6 vs 0,1; p<0,001).
Conclusion: Well-developed collaterals before reperfusion by PPCI in patients with
STEMI are associated with a protective effect on infarct size and MSI.Antiplatelet Agents and Anticoagulants
(TCTAP A-027 to TCTAP A-036)
TCTAP A-027
Comparison of On-treatment Platelet Reactivity After One-month Use of
Clopidogrel, Prasugrel or Ticagrelor in Koreans with Acute Coronary
Syndromes
Ji Hyun Lee, Sung Gyun Ahn, Jun-Won Lee, Young Jin Youn, Min-Soo Ahn,
Jang-Young Kim, Byung-Su Yoo, Seung-Hwan Lee, Junghan Yoon
Wonju Severance Christian Hospital, Wonju, Korea (Republic of)
Background: Prasugrel and ticagrelor have greater anti-ischemic efﬁcacy than clo-
pidogrel, but they are not widely used in East Asia owing to their increased risk of
bleeding. We compared on-treatment platelet reactivity (OPR) of these 3 drugs after 1
month in patients with acute coronary syndromes (ACS).
Methods:We assigned 95 patients undergoing percutaneous coronary intervention for
ACS to clopidogrel, prasugrel, or ticagrelor treatment. We measured OPR using the
VerifyNow P2Y12 assay. High OPR (HOPR) was deﬁned by P2Y12 reaction unit
(PRU) 240; low OPR (LOPR) was deﬁned by PRU <85. We compared the numbers
of patients with HOPR and LOPR after 1 month of antiplatelet treatment.
Results: OPR was lowest in the ticagrelor group (n¼25), followed by the pra-
sugrel (n¼34) and clopidogrel groups (n¼36, 4930 vs 8659 vs 17977,
p <0.001). HOPR was not noted in the prasugrel or ticagrelor groups, but was
noted in 5 clopidogrel-treated patients (13.9%, p¼0.007). The ticagrelor group
had the most number of patients with LOPR, followed by the prasugrel and
clopidogrel groups (88% vs 52.9% vs 13.9%, p <0.001). The clopidogrel
group had the highest number of patients in the therapeutic window of OPR (PRU
85–239) (Figure).Conclusion: HOPR to clopidogrel can be overcome by using prasugrel or ticagrelor.
However, prasugrel or ticagrelor increased LOPR, which may lead to excessive
bleeding events in East Asians.S8 JACC Vol 63/12/Suppl S j April 22–25, 2TCTAP A-028
Comparison of Platelet Aggregation Before & After Loading Dose of Prasugrel
and Clopidogrel in Percutaneous Coronary Intervention in Adult Pakistani
Coronary Artery Disease Patients
Ahmad Shahbaz1, Ahmad Nouman1, Khawar Mehdi2, Muhammad Azhar1
1PIC, Karachi, Pakistan, 2Getz Pharma, Karachi, Pakistan
Background: The use of dual antiplatelet therapy with aspirin and a thienopyridine is an
essential aspect of the supportive pharmacologic regimen administered to coronary artery
disease (CAD) patients who are undergoing primary percutaneous coronary intervention
(PCI). This study was carried out to compare the inhibition of platelet aggregation (IPA)
between prasugrel and clopidogrel in adult Pakistani patients undergoing primary PCI.
Methods: A total of hundred subjects were randomly assigned to two groups A & B.
GroupA (n¼50) received prasugrel (PRISA) 60mg loading dose pre PCI and 10mgQD
maintenance dose, whereas group B (n¼50) received clopidogrel 600mg loading and 75
mg BID maintenance dose respectively. Adenosine diphospahte (ADP) was used as
agonist before loading dose and post-PCI at 3-4 hours since it is themost commonly used
agonist, particularly in systems that measure only platelet aggregation in whole blood.
Results: Male and female ratio was 4:1 in both groups. Mean age was insigniﬁcant
between group A and group B (50.39.6 vs. 50.310.9; range: 29-68 and 23-71 years
respectively). In Group A (Prasugrel) n¼50; the respective occurrence of CAD was:
LAD n¼25 (50%), RCA n¼14 (28%), Cx Distal n¼5 (10%), MVD n¼3 (6%), Non-
stent 1 (2%) & others n¼2 (4%). In Group B (Clopidogrel) n¼50; the respective
occurrence of CADwas: LAD n¼23 (46%), RCA n¼11 (22%),MVD n¼8 (16%)&Cx
Distal n¼7 (14%) & others n¼1 (2%). None of the patient experienced minor or major
adverse cardiac events after taking loading dose in both groups. The before and after
loading dose mean platelet aggregation (MPA) responses were statistically signiﬁcant
within the two treatment groups (Group A: 6.082.12 vs 1.562.11; p<0.001 and
Group B: 4.272.06 vs 0.681.38; p<0.001). The mean reduction in platelet aggre-
gation by Group A (Prasugrel) was 74.4% and by Group B (Clopidogrel) was 51.8%.
Conclusion: Prasugrel 60 mg loading dose (PRISA) achieves signiﬁcantly greater
IPA as compared to clopidogrel 600 mg LD. Both drugs were well-tolerated and
adverse drug reactions were comparable.
TCTAP A-029
Low Dose Proton Pump Inhibitors in Patients Treated with Dual-antiplatelet
Therapy After Acute Coronary Syndrome
Yoshiki Nagata, Takuya Mayumi, Tomoya Harada, Masaki Kinoshita,
Isao Aburadani, Motoaki Hirazawa, Michiro Maruyama, Kazuo Usuda
Toyama Prefectural Central Hospital, Toyama, Japan
Background: The proton pump inhibitors (PPIs) with aspirin and clopidogrel are
frequently concomitantly used to prevent adverse gastrointestinal effects. However, it has
been reported that the antiplatelet action becomes attenuated when a PPI is used in com-
bination with clopidogrel. The Food and Drug Administration issued a warning against the
concomitant use of high dose (40 mg) esomeprazole/omeprazole with clopidogrel. This
warning has raised concerns that the addition of a PPI to clopidogrel in acute coronary
syndrome (ACS)patients could actually increase the risk of recurrent cardiovascular events.
Methods: The effect of PPIs causing platelet aggregation during the administration of
clopidogrel was investigated after primary percutaneous coronary intervention (PCI).
The subjects consisted of 122 cases of ACS. Platelet aggregation function testing
(light transmission intensity method) was conducted while aspirin and clopidogrel
75mg were orally taken before discharge. The minimum concentration of aggregation
induction (Platelet aggregation threshold index; PATI) was measured. The PATI,
measured with ADP as the inducing substance, was compared and investigated ac-
cording to the type of concomitantly used PPIs.
Results: The result of the PATI were: non-PPI group: 3.730.62 mM (N¼18) and PPI
group: 3.330.94mM (N¼104). The difference of type of PPI were rabeprazole (10
mg) group: 3.630.63 mM (N¼20), esomeprazole (20 mg) group 3.310.93 (N¼39)
and lansoprazole (15 mg) group: 3.211.06 mM (N¼42). The omeprazole group was
excluded, because the subjects were only 3 cases. The PATI of lansoprazole group
was the lower than the other groups (p <0.05 compared with non-PPI group).
Conclusion: The effect of CYP2C19 differs depending on the type of PPI, with a
difference being caused in the interaction with clopidogrel. The concomitant use of
low dose lansoprazole reduced the antiplatelet action of clopidogrel. The low dose
esomeprazole reduced the antiplatelet action, but the interaction effect was small.
Rabeprazole was least inﬂuence on the antiplatelet action. When PPI is used in
combination with dual-antiplatelet therapy in ACS patients, low dose esomeprazole
and rabeprazole should be consideration.
TCTAP A-030
Safety and Efﬁcacy of a Hybrid Dual Antiplatelet Therapy Regimen for ST-
elevation Myocardial Infarction Patients: A Single-centre Experience
Deanna Khoo, Yee May Wong, Hee Hwa Ho, Yau Wei Ooi, Paul Jau, Lueng Ong,
Fahim Haider Jafary, Kwok Kong Loh, Julian Tan, David Foo
Tan Tock Seng Hospital, Singapore, Singapore
Background: Prasugrel, a third generation thienopyridine is recognised as one of the
cornerstone treatment of contemporary dual antiplatelet therapy (DAPT) in selected
patients with ST- elevation myocardial infarction (STEMI) undergoing primary
percutaneous coronary intervention (PPCI). The incremental cost of prasugrel coupled014 j TCTAP Abstracts/ORAL/Antiplatelet Agents and Anticoagulants
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19th CardioVascular Summit: TCTAP 2014with a higher risk of bleeding have limited its widespread use. As the rates of early
stent thrombosis are higher especially in the early stages of STEMI, the use of a more
potent DAPT regimen in the initial period could potentially confer the most beneﬁt.
We therefore sought to evaluate the safety and efﬁcacy of a hybrid DAPT regimen
(involving a switch of prasugrel to clopidogrel at 1 month post MI) in STEMI patients
and report on the clinical outcomes.
Methods: From January to August 2012, 141 STEMI patients (94% male, mean age
54 + 9.2 years) were preloaded with 60 mg of prasugrel and 300 mg of aspirin in the
emergency room of our institution prior to PPCI. Patients aged > 75 years, body
weight < 60 Kg and those with previous history of stroke were excluded.
Upon hospital discharge, patients received maintenance doses of 10 mg of prasugrel
and 100 mg of aspirin for the ﬁrst 30 days. At 30 days post MI, prasugrel was stopped
and patients were loaded with 300 mg of clopidogrel followed by 75 mg as mainte-
nance dose (for the remaining 11 months in conjuction with aspirin). The primary
efﬁcacy end point was a composite of death from cardiovascular causes, nonfatal MI,
or nonfatal stroke at 1 year follow-up. The key safety end point was Thrombolysis in
Myocardial Infarction (TIMI) major bleeding at 1 year follow-up.
Results: PPCI was performed predominantly via the radial approach (86%) with
Clexane used as procedural anti-coagulant in 60% of patients (40% received heparin).
Glycoprotein IIb/IIIa inhibitors were administered in 82% of patients with the majority
(64%) receiving drug eluting stent implantation during PPCI.
The primary end point occurred in 6 patients (4.3%) with 4 events (2.8%) occurring
within the ﬁrst 30 days of MI. Death from cardiovascular causes occurred in 3 patients
(2.1%). Non-fatal MI occurred in 2 patients (1.4%) with 1 patient (0.7%) developing a
non-fatal stroke. Stent thrombosis occurred in 3 patients (2.1%) patients with 1 case of
probable stent thrombosis (0.7%) occurring within 30 days of MI.
Bleeding events were observed in 10 patients (7%) with TIMI major bleeding
episode occurring in 3 patients (2.1%). There was 1 bleeding episode occurring in the
setting of coronary artery bypass surgery.
Conclusion: Our preliminary experience showed that a hybrid DAPT regimen in a
selected group of STEMI patients is feasible, efﬁcacious and safe. The long term
clinical outcomes were good with a low incidence of ischaemic and bleeding events.
TCTAP A-031
Platelet Function Test and Bleeding Risk in Patients with Coronary Artery
Disease: A Case-control Study
Ho Fai Daniel Fong
Princess Margaret Hospital, HK, Hong Kong, China
Background: Management of coronary heart disease remains a challenge even with
modern advances. New anti-platelet agents which reduce thromboembolic events in
patients with coronary heart disease were introduced. However, there are concerns about
an increased in bleeding risk for patients taking these new anti-platelet agents. Platelet
function test, such as VerifyNow, claimed to be able to predict bleeding risk. However,
the evidence was limited, especially among the Asian population. This study aimed to
evaluate the use ofVerifyNow to assess bleeding risk. Subjectswith low residual platelet
reactivity, i.e. low PRU value, were hypothesized to have an increased bleeding risk.
Methods: This was a case control study performed in the Princess Margaret Hospital of
Hong Kong. A total of 120 subjects who were taking a P2Y12 inhibitor and had a
VerifyNow test were recruited. The cases were deﬁned as subjects with a PRU value of
less than or equal to 95, a threshold for increased bleeding risk as recommended by
Western studies. The controls were age matched to the cases. The primary outcome was
the increase in bleeding risk associated with a low PRU value at 30 days. The secondary
outcomewas the increase in bleeding risk associatedwith a lowPRUvalue at 1 year. The
use of the percentage of platelet inhibition was also evaluated as a secondary outcome.
Multivariable logistic regression was used to obtain the odds ratio of the low PRUgroup.
Results: Bleeding events occurred more frequently in the low PRU group. At 30 days,
31.7% of subjects among the case had a bleeding event while 43.3% of the cases had a
bleeding event at 1 year. The majority of these bleeding events were minor bleeding,
such as easy bruising. After adjusting for confounders, there was no statistically
signiﬁcant increase in bleeding risk among those in the low PRU group at 30 days or 1
year. Subjects with a high percentage of platelet inhibition (>50%) was also not
associated with a statistically signiﬁcant increase in bleeding risk.
Conclusion: A low PRU value was not associated with an increased bleeding risk at 30
days. Thus the VerifyNow test was not shown to be useful in assessing the bleeding risk of
patients in anAsian population, contrary to theﬁndings fromWestern literature.A possible
explanation was that the VerifyNow threshold for predicting bleeding might be higher
among the Asian population. The deﬁnition for low residual platelet reactivity might be
different in our locality. A larger sample size might also be needed. Further studies are
needed to evaluate whether a different cut off is more optimal for the Asian population.
TCTAP A-032
Comparison of Platelet Reactivity and Clinical Outcomes in Patients Treated
with Clopidogrel and Coronary Intervention
Sang Yeub Lee, Ju-Hee Lee, Sang Min Kim, Jang-Whan Bae, Kyung-Kuk Whang,
Dong-oon Kim, Myeong-Chan Cho
Chungbuk National University Hospital, Cheongju, Korea (Republic of)
Background: Platelets are associated with vascular occlusive event. High on-clopi-
dogrel platelet reactivity (HPR) is associated with recurrent thrombotic events after
percutaneous coronary intervention (PCI). We evaluated platelet reactivity measured
by the VerifyNow P2Y12 assay and clinical outcomes in patients receiving clopi-
dogrel and PCI of real world practice.JACC Vol 63/12/Suppl S j April 22–25, 2014 j TCTAP Abstracts/ORAMethods: We recruited A total of 878 consecutive clopidogrel-treated patients un-
dergoing emergent or elective PCI. The main outcome measures were cardiovascular
(CV) death, deﬁnite/probable stent thrombosis (ST), nonfatal myocardial infarction
(MI), coronary revascularization and a composite end point of ischemic events. We
assessed Platelet reactivity 12 hours later by measuring P2Y12 reactivity unit (PRU)
with VerifyNow P2Y12 assay (Accumetrics, San Diego, California). High platelet
reactivity (HPR) was deﬁned as PRU value  240 or 280.
Results: In total, 877 consecutive patients were enrolled. Patients with HPR were 454
(Male, 284). In all patients, coronary stent was implanted. All patients received clo-
pidogrel pretreatment (300mg loading dose), received a maintenance dose of 75 mg
daily. The composite end points of the study at follow-up of 12 months were CV
death, nonfatal MI, and coronary revascularization. At a 12-month follow-up, we
found 85 ischemic events (26 CV deaths [3.4%], 11 nonfatal MIs [1.4%]) and 56
target-vessel revascularizations (7.1%). The composite event rate of patients with HPR
(PRU > 240) was signiﬁcantly higher (7.5% vs 4.3% (p ¼ 0.047)) than the patient
with normal value. In survival analysis, there was no signiﬁcant difference between
patient with HPR (PRU > 240) and normal reactivity. But between patient with HPR
(PRU > 280) and normal reactivity, the survival rate free from the primary end point
was signiﬁcantly lower in patients with HPR (p ¼ 0.014, Generalized Wilcoxon test).
Conclusion: High on-clopidogrel platelet reactivity tested by VerifyNow predict
coronary adverse event in patients after PCI. In Korean, we seem to have to raise the
optimal cutoff value of PRU to predict future coronary event.
TCTAP A-033
Reappraisal of Pharmacodynamic Effect of Adjunctive Cilostazol and High-dos
Clopidogrel in East Asian ACS Patients
Young-Hoon Jeong, Yongwhi Park, Jin Sin Koh, Jin-Yong Hwang
Gyeongsang National, Jinju, Korea (Republic of)
Background: Compared with Westerners, East Asians have shown different thera-
peutic level of platelet reactivity (PR) regarding post-PCI ischemic and bleeding
events. We also reported different therapeutic level for East Asians (35% < 20 mM
ADP-PR < 70%). We reappraised the pharmacodynamic effect of adjunctive cil-
ostazol and high-dose clopidogrel in East Asians based on this criteria.
Methods: PCI-treated ACS patients were assigned to either clopidogrel 150 mg/d
(DOUBLE; n¼139) or cilostazol 100 mg bid + clopidogrel 75 mg/d (TRIPLE; n¼136)
on top of aspirin. PR was measured at least 30-day follow-up with light transmittance
aggregometry. Primary endpoint was the prevalence of HPR at follow-up.
Results: DOUBLE and TRIPLE together showed low prevalences of HPR (9.4% and
2.2%, respectively). Although the level of PR in TRIPLE increased according to the
number of CYP2C19 loss-of-function (LoF) allele (p¼0.015), HPR risk was almost
overcome irrespective of CYP2C19 phenotype (p¼0.633). The level of PR and HPR
risk in DOUBLE increased proportionally depending on CYP2C19 phenotype
(p<0.001 and p¼0.006, respectively). In multivariate analysis, carriage of 2
CYP2C19 LoF alleles only increased HPR risk by 8.5-fold in DOUBLE.
Conclusion: Our results support clinical usefulness of TRIPLE in East Asians based
on pharmacodynamic data. Clinical efﬁcacy and safety of more potent P2Y12 in-
hibitor, prasugrel and ticagrelor, must be reevaluated separately in this unique race.TCTAP A-034
Observational Studies of Bleeding and Thrombotic Events in Acute Coronary
Syndrome Patients Between Different Metabolizer of Clopidogrel
Wen Duo Zhang, Fu Sui Ji
Beijing Hospital, Beijing, China
Background: Compared with CYP2C19*1 carriers，CYP2C19*2,*3 carriers have
a higher risk of stent thrombosis in clopidogrel-treated patients. ThereforeL/Antiplatelet Agents and Anticoagulants S9
